Reading time: 4 minutes Karli Norville In 2021, lung cancer was ranked as the number one cause of cancer deaths in the United States (1). The American Cancer Society reports that the 5-year survival rate of all Non-Small Cell Lung Cancer (NSCLC) patients is 26% (2). A recent study of the cancer drug Lorlatinib announced... Continue Reading →
Reading time: 5 minutes Karli Norville Immune checkpoint inhibitors (ICIs) have been so impactful in the treatment of cancer in recent years that the basic research supporting their development was the subject of the 2018 Nobel Prize in Physiology or Medicine (1). Despite their clinical success, the occurrence of immune-related adverse events (irAEs) within a... Continue Reading →
Reading time: 6 minutes Karli Norville It can take more than ten years to move a drug or therapeutic from discovery to FDA approval. Despite the years of research put in before a clinical trial begins, many therapeutics fail due to unforeseen safety complications or their lack of efficacy. Why do so many fail? Despite... Continue Reading →
OncoBites 